Great synopsis Master S, here's my take...
Let me add, as I monitored all last week, it looked like most of the trading was cashing out board lots less than 100 shares, the buying looked like they were trying to fulfill the 400 shareholder minimum guideline to meet NASDAQ, and NYSE guidelines.
It is apparent that they did a great job in the debt restructuring and are focused on making their vaccine platform [Tap technology] world class .
1: They have many directions to go. Not only does their pipeline encompass approx 84% of the HER2neu population but may be extended beyond just Breast and Ovarian Cancer this may very well make them a highly regarded takeover candidate. At a premium much higher than where we stand today, their vaccines also seem to be complimentary to many other medical applications.
2. Although their trials may not be as advanced as some other companies, with the adequate funding in place they will be able to fast track their technology and make up that ground.
3. Partner with a well selected pharmaceutical Co.
4. Spin off their Bio-defence arm to another company in that space, or spin it off to us shareholders.
5. Strong Patent protection and focused on making it stronger.
It truly is an inspiring platform and seems to be the "only" and "most comprehensive" to date. I have been in the company for approx, 5 years and the future looks very bright if their technology is as sound as initial data implies.
Wilfred Jefferies who was the one who started it all back in the late 90's was confident that the TAP technology was ground breaking even then, we are very close to seeing if his work was sound. If it is this stock will be one of the most sought after in the world.
I have traded for many years and this is one of the best restructurings I have seen, with the perfect technology, in the right space at the right time that I can remember. I see very few flaws that the likes of Seeking Alpha and other cronies will be able to discredit, as most if not all research has been documented in Peer Reviewed Journals.
It appears that we may in the perfect storm with Tapimmune, the next six months will tell, safety and efficacy in the Phase 1 trial seem to have been met.
Tapimmune needs to bring Phase 1 clinical update as soon as possible, I am sure that they are working diligently to advance all fronts.
Look for press sometime next week, and financing in the near future, when that is put in place it makes Tapimmune a much sought after entity. I expect that they will get their listing on either NASDAQ or NYSE in 2014 maybe within months.
GLTA,existing shareholders like myself who is a big buyer at these levels, and welcome all new shareholders. With a financing of 5 to 6 million shares any where over $2.50 but more likely over $3 we raise approx $15 million,enough to fund them through 2014 and beyond, with only approx 22 to 25 million outstanding shares and a very tight float that will jump with any substantial buying. Next financing will be done at much higher levels, float is tied to the restructuring so may be a hold on any selling for 3 to 6 months. Which means that trying to wait for the share price to back of substantially may mean missing out on the first big move which in my opinion is coming soon.
Tapimmune seems like one of the rare R/S stories that will succeed, shorties not only have very little stock to accumulate, but run the risk of getting slaughtered when the real data becomes available.
Look forward to Tapimmune's future and hearing other's take on their technology who may be better versed on the medical side of the story.
GLTA: Strong Buy
